Capital
Solutions
rESOURCING
We can facilitate resourcing of your clinical development at both the enterprise and clinical programme level. We offer start-up businesses unique resourcing solutions for their early phase research: safety to pivotal studies. Proof-of-concept and Pivotal studies are the most fundamental value inflection points in the clinical journey, and therefore we understand the importance of achieving these milestones on the road to success.
VARYING DEGREES OF SUPPORT
Vx Pharma offers varying degrees of financial support ranging from highly discounted pricing through to fully funded programmes in exchange for select Fractional Ownership of geographic or indication intellectual property (IP) rights to your therapeutic assets. Our unique Fractional IP Resourcing model focuses on the non-core IP fractions of our clients’ IP portfolio.
Our model is similar to Synthetic Royalty Financing, a non-dilutive solution helping emerging biopharma (EBP) companies unlock early value to assist in bootstrapping their business objectives.
VALUE-TO-QUALITY SOLUTIONS
We operate in jurisdictions that offer the best value-to-quality clinical development solutions. We have chosen our execution partners in these jurisdictions based on decades of successful historical partnering on clinical development projects. Vx Pharma leverages these exceptional relationships to deliver unparalleled value to our clients’ development programmes.
rESOURCING
We can facilitate resourcing of your clinical development at both the enterprise and clinical programme level. We offer start-up businesses unique resourcing solutions for their early phase research: safety to pivotal studies. Proof-of-concept and Pivotal studies are the most fundamental value inflection points in the clinical journey, and therefore we understand the importance of achieving these milestones on the road to success.
VARYING DEGREES OF SUPPORT
Vx Pharma offers varying degrees of financial support ranging from highly discounted pricing through to fully funded programmes in exchange for select Fractional Ownership of geographic or indication intellectual property (IP) rights to your therapeutic assets. Our unique Fractional IP Resourcing model focuses on the non-core IP fractions of our clients’ IP portfolio.
Our model is similar to Synthetic Royalty Financing, a non-dilutive solution helping emerging biopharma (EBP) companies unlock early value to assist in bootstrapping their business objectives.
VALUE-TO-QUALITY SOLUTIONS
We operate in jurisdictions that offer the best value-to-quality clinical development solutions. We have chosen our execution partners in these jurisdictions based on decades of successful historical partnering on clinical development projects. Vx Pharma leverages these exceptional relationships to deliver unparalleled value to our clients’ development programmes.
